Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Patient Monitoring
verinata.com

See what CB Insights has to offer

Founded Year

2001

Stage

Acquired | Acquired

Total Raised

$76.57M

Valuation

$0000 

About Verinata Health

Verinata Health, formerly Artemis Health, develops and offers non-invasive tests for early identification of fetal chromosomal abnormalities using proprietary technology. The company aims to reduce the anxiety associated with multi-step processes, false-positive rates, non-specified results of current prenatal screening methods, as well as the risk of invasive procedures. Verinata is conducting a prospective, blinded pivotal study to clinically validate the sensitivity and specificity of its first prenatal test on a large scale.In January 2013, Verinata Health was acquired by Illumina. The valuation of Verinata Health was $350 million. Other terms of the deal were not released.

Verinata Health Headquarter Location

1531 Industrial Road

San Carlos, California, 94070,

United States

650-323-4300

Latest Verinata Health News

BioReference Labs Acquires US Ariosa Lab NIPT Business From Roche

Aug 17, 2021

Save for later NEW YORK – Opko subsidiary BioReference Laboratories announced on Monday that it has acquired the US Ariosa centralized lab prenatal testing business from Roche. Financial and other terms of the deal were not disclosed. Ariosa's noninvasive prenatal screening test, the Harmony Prenatal Test, has been performed in more than 1.5 million patients. The acquisition will complement BioReference's specialty health division GenPath, which currently offers the ClariTest Core. Both tests use the same core technology, BioReference said in a statement. "Acquiring the US Ariosa centralized laboratory prenatal testing business allows us to expand our [noninvasive prenatal screening] offerings and further underscores our commitment to prenatal screening," Jon Cohen, executive chairman of BioReference, said in a statement. In May, Ariosa and Illumina settled a long-running patent dispute across four cases over sequencing-related methods used in NIPT that began when Verinata Health  filed suit  against Ariosa in 2012. Verinata was then acquired by Illumina, which  sued  in 2014 and 2015 for patent infringement. Ariosa countersued for non-infringement, invalidity of the patents, breach of the covenant of good faith and fair dealing, and breach of contract. In 2018, a jury awarded Illumina  $26.7 million  in damages for the 2014 lawsuit, which the US Court of Appeals for the Federal Circuit affirmed in 2020.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Verinata Health

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Verinata Health in 1 CB Insights research brief, most recently on Jan 20, 2021.

Expert Collections containing Verinata Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Verinata Health is included in 1 Expert Collection, including Omics.

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Verinata Health Patents

Verinata Health has filed 63 patents.

The 3 most popular patent topics include:

  • Genetics
  • Molecular biology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/31/2017

9/28/2021

Genetics, Molecular biology, Rare diseases, DNA, Autosomal recessive disorders

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/31/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/28/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Genetics, Molecular biology, Rare diseases, DNA, Autosomal recessive disorders

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.